In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp.
about
New methods to assess susceptibilities of Aspergillus isolates to caspofungin.Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasisVoriconazole in the management of nosocomial invasive fungal infections.Simple fluorescence-based high throughput cell viability assay for filamentous fungi.Anidulafungin: review of a new echinocandin antifungal agent.A review of clinical experience with newer antifungals in childrenVoriconazole in the treatment of fungal osteomyelitis of the orbit in the immunocompromised host.Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidiaEchinocandin antifungals: review and update.Emerging echinocandins for treatment of invasive fungal infections.Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations.Population pharmacokinetic-pharmacodynamic analysis of anidulafungin in adult patients with fungal infections.The safety of anidulafungin.Micafungin: a new echinocandin antifungal.The echinocandins.Anidulafungin in the treatment of invasive fungal infections.New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.In vitro activity of anidulafungin against selected clinically important mold isolatesPharmacokinetics, antifungal activity and clinical efficacy of anidulafungin in the treatment of fungal infections.Palliative dental care- a boon for debilitating.Caspofungin for the treatment of immunocompromised and severely ill children and neonates with invasive fungal infectionsComparison of the Sensititre YeastOne colorimetric antifungal panel with a modified NCCLS M38-A method to determine the activity of voriconazole against clinical isolates of Aspergillus spp.Voriconazole: a broad spectrum triazole for the treatment of serious and invasive fungal infections.Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis.In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method.Anidulafungin and its role in candida infectionsIn vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin.Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal.Safety and pharmacokinetics of coadministered voriconazole and anidulafungin.Early clinical experience with anidulafungin at a large tertiary care medical center.Filter Adsorption of Anidulafungin to a Polysulfone-Based Hemofilter During CVVHD In Vitro.Safety of anidulafungin in solid organ transplant recipientsGlucan Synthase Inhibitors
P2860
Q34956645-266FCBDD-E722-4E73-B713-B24137C5A848Q35127833-75E5BB29-5B60-414A-9056-09CB34F09817Q35166823-DFA93E9B-7353-4F20-ADB6-60450EE48385Q35676526-3476C9E4-7FFD-422B-8F97-58F89C415053Q35917456-DCD04BF3-E8AB-4653-9B94-9C343B39FEEAQ36290698-DA12E867-F3BB-4FCB-82D3-195A6C1CFBA7Q36342105-7F932F93-E2CB-4DF2-9C29-B1555BCC202BQ36422666-4772AFC0-7317-49F0-AABF-EE5007CC2405Q36441524-51AD9554-AD60-4B4A-99B4-5FFD957DDD42Q36458402-CB04F235-C24C-402F-97D4-96250B5F7412Q36491819-5C0280AC-3346-4437-A2B8-9871566F7783Q36505401-264FD93A-88AB-4AC9-A8D6-AB2C338DA957Q36624970-074D5EC0-D25E-49A8-8EB9-23E018ABC8AFQ36693843-196B89E5-8B9C-4FBF-807F-843CCF5688B6Q36742397-2001E3A8-BB75-4234-AB42-5AC92E6DC783Q36822941-2E1DDA37-CAD0-499A-A11F-93D3FED2492BQ37608276-F69EEEA9-4607-4EBC-A4E5-1D7805E669A1Q37734590-F2C59294-9110-478F-B53B-8F722A265657Q37785979-EDDAF673-A888-48F8-B98E-D4685B7A704BQ38239696-6AE42758-ED66-4B5B-88F5-62535BAEA5B3Q39701953-B11B9B9D-1D4B-4C30-8C7A-056E505618D3Q39989843-2DD21A5F-1687-459F-AAB3-983FEFD41B60Q40189236-6BFDE666-FF65-49B2-A5A6-17843B17606BQ42064852-DF7323BA-E52F-44C9-B732-2BF9CAC01088Q42576501-F9393041-34E0-4843-BED1-2B11B222C248Q42731827-EFB3959D-5E95-4B9C-B4E4-A7F2F70B7DC9Q43169846-5EFFEBC5-8CD1-41E1-B2B6-0B35D5EFDF3FQ44897892-8D41411D-165D-4C6A-A97F-C344FEA8C4A5Q46807629-6D4AAB0E-4F42-40D9-A977-D65E2547E5B2Q46836740-1076A473-1EB5-4E07-BC54-A34681627411Q48192025-F3594C81-CCFC-4408-A909-D6205E5ADBE1Q57569012-645708DB-668B-445A-B8EF-AFAE9923A8B3Q58033533-CC12A665-B9D0-49C8-A0B0-D76109E1240E
P2860
In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
In vitro activity of voriconaz ...... cin B against aspergillus spp.
@en
In vitro activity of voriconaz ...... cin B against aspergillus spp.
@nl
type
label
In vitro activity of voriconaz ...... cin B against aspergillus spp.
@en
In vitro activity of voriconaz ...... cin B against aspergillus spp.
@nl
prefLabel
In vitro activity of voriconaz ...... cin B against aspergillus spp.
@en
In vitro activity of voriconaz ...... cin B against aspergillus spp.
@nl
P2093
P1476
In vitro activity of voriconaz ...... cin B against aspergillus spp.
@en
P2093
Anastasio Valverde-Conde
María del Carmen Serrano
Mercedes Ramirez
Mónica Chávez M
Rosa María Claro
Samuel Bernal
P304
P356
10.1016/S0732-8893(02)00507-2
P577
2003-02-01T00:00:00Z